search

1-20 of 32

Save search

Sort by

Sort Order Select

Journal Article

7-Year (2015–21) longitudinal surveillance of lefamulin in vitro activity against bacterial pathogens collected worldwide from patients with respiratory tract infections including pneumonia and characterization of resistance mechanisms

PDF

Susanne Paukner and others

Journal of Antimicrobial Chemotherapy, Volume 79, Issue 2, February 2024, Pages 360–369, https://doi.org/10.1093/jac/dkad389

Published: 19 December 2023

Supplementary data

Journal Article

Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018–19)

PDF

Helio S Sader and others

Journal of Antimicrobial Chemotherapy, Volume 77, Issue 10, October 2022, Pages 2642–2649, https://doi.org/10.1093/jac/dkac233

Published: 28 July 2022

Supplementary data

Journal Article

In vitro activity of the orally bioavailable ceftibuten/VNRX-7145 (VNRX-5236 etzadroxil) combination against a challenge set of Enterobacterales pathogens carrying molecularly characterized β-lactamase genes

PDF

Rodrigo E Mendes and others

Journal of Antimicrobial Chemotherapy, Volume 77, Issue 3, March 2022, Pages 689–694, https://doi.org/10.1093/jac/dkab425

Published: 28 November 2021

Supplementary data

Journal Article

Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime/avibactam, meropenem/vaborbactam and comparators against these isolates

PDF

Mariana Castanheira and others

Journal of Antimicrobial Chemotherapy, Volume 76, Issue 12, December 2021, Pages 3125–3134, https://doi.org/10.1093/jac/dkab306

Published: 30 August 2021

Journal Article

Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019

PDF

Rodrigo E Mendes and others

Journal of Antimicrobial Chemotherapy, Volume 76, Issue 11, November 2021, Pages 2833–2838, https://doi.org/10.1093/jac/dkab279

Published: 26 August 2021

Supplementary data

Journal Article

Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019

PDF

Helio S Sader and others

Journal of Antimicrobial Chemotherapy, Volume 76, Issue 3, March 2021, Pages 659–666, https://doi.org/10.1093/jac/dkaa504

Published: 04 December 2020

Journal Article

Combination of MexAB-OprM overexpression and mutations in efflux regulators, PBPs and chaperone proteins is responsible for ceftazidime/avibactam resistance in Pseudomonas aeruginosa clinical isolates from US hospitals

PDF

Mariana Castanheira and others

Journal of Antimicrobial Chemotherapy, Volume 74, Issue 9, September 2019, Pages 2588–2595, https://doi.org/10.1093/jac/dkz243

Published: 21 June 2019

Journal Article

Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA and Europe (2014–17)

PDF

Cecilia G Carvalhaes and others

Journal of Antimicrobial Chemotherapy, Volume 74, Issue 7, July 2019, Pages 1928–1933, https://doi.org/10.1093/jac/dkz120

Published: 01 April 2019

Journal Article

Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres

PDF

Helio S Sader and others

Journal of Antimicrobial Chemotherapy, Volume 74, Issue 5, May 2019, Pages 1306–1310, https://doi.org/10.1093/jac/dkz006

Published: 07 February 2019

Supplementary data

Journal Article

Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015–17)

PDF

Helio S Sader and others

Journal of Antimicrobial Chemotherapy, Volume 73, Issue 11, November 2018, Pages 3053–3059, https://doi.org/10.1093/jac/dky279

Published: 27 July 2018

Supplementary data

Journal Article

Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015–16

PDF

Michael A Pfaller and others

Journal of Antimicrobial Chemotherapy, Volume 73, Issue 10, October 2018, Pages 2748–2756, https://doi.org/10.1093/jac/dky235

Published: 29 June 2018

Journal Article

ZAAPS programme results for 2016: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 42 countries

PDF

Rodrigo E Mendes and others

Journal of Antimicrobial Chemotherapy, Volume 73, Issue 7, July 2018, Pages 1880–1887, https://doi.org/10.1093/jac/dky099

Published: 06 April 2018

Journal Article

Antimicrobial activity of oritavancin and comparator agents when tested against Gram-positive bacterial isolates causing infections in cancer patients (2014–16)

PDF

Michael A Pfaller and others

Journal of Antimicrobial Chemotherapy, Volume 73, Issue 4, April 2018, Pages 916–922, https://doi.org/10.1093/jac/dkx485

Published: 25 December 2017

Journal Article

ZAAPS Program results for 2015: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 32 countries

PDF

Michael A Pfaller and others

Journal of Antimicrobial Chemotherapy, Volume 72, Issue 11, November 2017, Pages 3093–3099, https://doi.org/10.1093/jac/dkx251

Published: 25 July 2017

Journal Article

Longitudinal (2001–14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010–13) analysis of oritavancin in vitro potency

PDF

Rodrigo E. Mendes and others

Journal of Antimicrobial Chemotherapy, Volume 71, Issue 12, 1 December 2016, Pages 3453–3458, https://doi.org/10.1093/jac/dkw319

Published: 08 September 2016

Supplementary data

Journal Article

Surveillance for linezolid resistance via the Zyvox^® Annual Appraisal of Potency and Spectrum (ZAAPS) programme (2014): evolving resistance mechanisms with stable susceptibility rates

PDF

Rodrigo E. Mendes and others

Journal of Antimicrobial Chemotherapy, Volume 71, Issue 7, July 2016, Pages 1860–1865, https://doi.org/10.1093/jac/dkw052

Published: 23 March 2016

Journal Article

In vivo emergence of ceftaroline resistance during therapy for MRSA vertebral osteomyelitis

PDF

Edgar H. Sanchez and others

Journal of Antimicrobial Chemotherapy, Volume 71, Issue 6, June 2016, Pages 1736–1738, https://doi.org/10.1093/jac/dkw001

Published: 09 February 2016

Journal Article

Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011–13)

PDF

Rodrigo E. Mendes and others

Journal of Antimicrobial Chemotherapy, Volume 71, Issue 1, January 2016, Pages 276–278, https://doi.org/10.1093/jac/dkv303

Published: 07 October 2015

Supplementary data

Journal Article

Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010–13) Get access

PDF

Rodrigo E. Mendes and others

Journal of Antimicrobial Chemotherapy, Volume 70, Issue 2, February 2015, Pages 498–504, https://doi.org/10.1093/jac/dku421

Published: 31 October 2014

Journal Article

MSSA ST398/t034 carrying a plasmid-mediated Cfr and Erm(B) in Brazil Get access

PDF

Ana C. Gales and others

Journal of Antimicrobial Chemotherapy, Volume 70, Issue 1, January 2015, Pages 303–305, https://doi.org/10.1093/jac/dku366

Published: 26 September 2014

Modify your search

Availability

NARROW

Format

Type

Section

Publication date

7-Year (2015–21) longitudinal surveillance of lefamulin in vitro activity against bacterial pathogens collected worldwide from patients with respiratory tract infections including pneumonia and characterization of resistance mechanisms

Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018–19)

In vitro activity of the orally bioavailable ceftibuten/VNRX-7145 (VNRX-5236 etzadroxil) combination against a challenge set of Enterobacterales pathogens carrying molecularly characterized β-lactamase genes

Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime/avibactam, meropenem/vaborbactam and comparators against these isolates

Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019

Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019

Combination of MexAB-OprM overexpression and mutations in efflux regulators, PBPs and chaperone proteins is responsible for ceftazidime/avibactam resistance in Pseudomonas aeruginosa clinical isolates from US hospitals

Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA and Europe (2014–17)

Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres

Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015–17)

Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015–16

ZAAPS programme results for 2016: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 42 countries

Antimicrobial activity of oritavancin and comparator agents when tested against Gram-positive bacterial isolates causing infections in cancer patients (2014–16)

ZAAPS Program results for 2015: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 32 countries

Longitudinal (2001–14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010–13) analysis of oritavancin in vitro potency

Surveillance for linezolid resistance via the Zyvox^® Annual Appraisal of Potency and Spectrum (ZAAPS) programme (2014): evolving resistance mechanisms with stable susceptibility rates

In vivo emergence of ceftaroline resistance during therapy for MRSA vertebral osteomyelitis

Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011–13)

Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010–13) Get access

MSSA ST398/t034 carrying a plasmid-mediated Cfr and Erm(B) in Brazil Get access

Email alerts

Modify your search

Publication date

7-Year (2015–21) longitudinal surveillance of lefamulin in vitro activity against bacterial pathogens collected worldwide from patients with respiratory tract infections including pneumonia and characterization of resistance mechanisms Free

Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018–19) Free

In vitro activity of the orally bioavailable ceftibuten/VNRX-7145 (VNRX-5236 etzadroxil) combination against a challenge set of Enterobacterales pathogens carrying molecularly characterized β-lactamase genes Open Access

Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime/avibactam, meropenem/vaborbactam and comparators against these isolates Open Access

Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019 Open Access

Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019 Free

Combination of MexAB-OprM overexpression and mutations in efflux regulators, PBPs and chaperone proteins is responsible for ceftazidime/avibactam resistance in Pseudomonas aeruginosa clinical isolates from US hospitals Free

Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA and Europe (2014–17) Free

Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres Free

Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015–17) Free

Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015–16 Free

ZAAPS programme results for 2016: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 42 countries Free

Antimicrobial activity of oritavancin and comparator agents when tested against Gram-positive bacterial isolates causing infections in cancer patients (2014–16) Free

ZAAPS Program results for 2015: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 32 countries Free

Longitudinal (2001–14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010–13) analysis of oritavancin in vitro potency Free

Surveillance for linezolid resistance via the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) programme (2014): evolving resistance mechanisms with stable susceptibility rates Free

In vivo emergence of ceftaroline resistance during therapy for MRSA vertebral osteomyelitis Free

Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011–13) Free

Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010–13) Get access

MSSA ST398/t034 carrying a plasmid-mediated Cfr and Erm(B) in Brazil Get access

Email alerts

This Feature Is Available To Subscribers Only

7-Year (2015–21) longitudinal surveillance of lefamulin in vitro activity against bacterial pathogens collected worldwide from patients with respiratory tract infections including pneumonia and characterization of resistance mechanisms

Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018–19)

In vitro activity of the orally bioavailable ceftibuten/VNRX-7145 (VNRX-5236 etzadroxil) combination against a challenge set of Enterobacterales pathogens carrying molecularly characterized β-lactamase genes

Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime/avibactam, meropenem/vaborbactam and comparators against these isolates

Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019

Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019

Combination of MexAB-OprM overexpression and mutations in efflux regulators, PBPs and chaperone proteins is responsible for ceftazidime/avibactam resistance in Pseudomonas aeruginosa clinical isolates from US hospitals

Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA and Europe (2014–17)

Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres

Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015–17)

Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015–16

ZAAPS programme results for 2016: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 42 countries

Antimicrobial activity of oritavancin and comparator agents when tested against Gram-positive bacterial isolates causing infections in cancer patients (2014–16)

ZAAPS Program results for 2015: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 32 countries

Longitudinal (2001–14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010–13) analysis of oritavancin in vitro potency

Surveillance for linezolid resistance via the Zyvox^® Annual Appraisal of Potency and Spectrum (ZAAPS) programme (2014): evolving resistance mechanisms with stable susceptibility rates

In vivo emergence of ceftaroline resistance during therapy for MRSA vertebral osteomyelitis

Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011–13)